Following the COVID-19 pandemic, mRNA-based vaccines have been shown to provide rapid and precise immune responses, however, this technology has much wider applications. Many leading pharma and ...

A few years ago, Moderna (NASDAQ: MRNA) stock soared on the back of the highly successful vaccine it developed in record time. At its peak in 2021, Moderna traded for over $450 per share.

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.

After hours: March 18 at 7:59:54 PM EDT Loading Chart for MRNA ...